follow us
Perth - The approach to
Understanding Risk Stratification
The concept of risk stratification in breast cancer screening focuses on tailoring the frequency and type of imaging based on a woman's specific risk profile. Currently, the BreastScreen program primarily recommends annual screenings for women with a significant family history of breast or ovarian cancer, while others are screened biennially. Despite the wealth of knowledge regarding risk factors for breast cancer, such as breast density, there has been a lag in translating this information into practical screening protocols. This gap has limited opportunities for early detection and effective risk management, ultimately impacting patient outcomes.
Key Risk Factors and Technological Innovations
Breast density is recognized as a critical risk factor, with women possessing dense breast tissue facing a higher likelihood of developing breast cancer and having undetected tumors during screenings. BreastScreen has begun notifying women about their breast density and has provided guidelines for general practitioners to assist in consultations. However, there are ongoing discussions about the best methods to communicate these risks and the potential for additional imaging options, such as 3D mammography and MRI.
Family history and genetic predispositions also play a vital role in assessing individual risk. Online tools like iPrevent and CanRisk allow women to evaluate their risk based on personal and familial data, facilitating informed discussions with healthcare providers. Furthermore, advancements in artificial intelligence are being explored to enhance mammography interpretation and predict future disease risk, potentially easing the workload for radiologists and improving patient outcomes. A trial of an AI model utilizing Australian data is currently underway in BreastScreen Victoria, with plans for expansion to South Australia.
Despite these promising developments, the pathways for effectively utilizing risk information remain under construction. There is a pressing need for innovative screening technologies and collaborative efforts with stakeholders to establish clear management strategies for women across various risk categories. Pilot studies will be essential to assess the feasibility of these new approaches before broader implementation. In the interim, women are encouraged to continue regular screenings and consult their healthcare providers regarding any new symptoms or concerns related to breast health.
